The EarLens System Long Term Safety and Efficacy Definitive Multi-Center Study
Primary Purpose
Hearing Impairment
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Sound amplification provided via EarLens System.
Sponsored by
About this trial
This is an interventional treatment trial for Hearing Impairment focused on measuring Hearing impairment, Hearing loss
Eligibility Criteria
Inclusion Criteria:
- Age 18 to 85 years
- Mild to severe hearing impairment between 125 to 4000 Hz
- No significant conductive hearing impairment
- Able and willing to commit to travel and time demands of the study
Exclusion Criteria:
Must not have known or active medical issues that would preclude having a device including:
- an abnormal tympanic membrane
- an abnormal middle ear or history of prior middle ear surgery other than tympanostomy tubes
- an ear canal anatomy that prevents physicians from seeing adequate amount of the tympanic membrane
Must not have other known or active medical issues including:
- history of chronic and recurrent ear infections in the past 24 mouths
- history of dizziness and/or vertigo in the past 24 months
- taking medications/treatments with known ototoxic effects
- a rapidly progressive or fluctuating hearing impairment
- having been diagnosed with having a compromised immune system
- Must not fit the definition of a vulnerable subject, as per FDA regulations 21 CFR Parts 50 and 56
- Must not have an ear canal anatomy that preclude manufacture of the device as determined by EarLens manufacturing personnel
Sites / Locations
- EarLens Corporation
- Camino Ear Nose and Throat Clinic
- University of Iowa Hospitals and Clinics
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Mild to severe hearing impairment
Arm Description
Sound amplification provided via the EarLens System assistive hearing device.
Outcomes
Primary Outcome Measures
Change in Mean Aided Word Recognition Scores (WRS) When Compared to the Baseline Unaided Condition.
Change in mean aided Word Recognition Scores (WRS) when compared to the baseline unaided condition. WRS will be measured using 50-word NU-6 (Northwestern University Auditory Test No.6) recorded materials, presented at 45 dB Hearing Level on a per-ear basis with the test ear isolated for measurement and the results, expressed as a percentage of words correct, averaged across the two ears for each subject. All subject data will then be averaged to obtain the means. The baseline unaided measurements will occur prior to device placement, and the aided condition will be measured at least 30 days post device placement.
Audiometric Safety as Shown by no Hearing Change Pre and Post Treatment
The unaided air conduction hearing thresholds will be measured for each individual ear twice before device placement at Visit #1 and averaged to obtain the baseline unaided air conduction hearing thresholds, and the post wear unaided air conduction hearing thresholds will be measured after device removal at Visit #5. A PTA4 (Pure Tone Average at 4 frequencies; 500, 1000, 2000, and 4000 Hz) will be computed both for baseline unaided hearing pre-placement and unaided hearing post-removal for each ear, then averaged across both ears for each subject . A determination of "No Hearing Change" for the subject population will be made if the calculated Hearing Changes of the subject population are 10 dB or less.
Secondary Outcome Measures
Functional Gain Over the Frequency Range From 2000 to 10,000 Hz
10 dB (decibel) change in the averaged pure tone thresholds for the subject population over the frequency range from 2000 to 10,000 Hz (2000, 3000, 4000, 6000, 8000, 9000 and 10,000 Hz). Measurement to be used in analysis are the baseline unaided soundfield thresholds measured prior to device placement and the aided soundfield thresholds measured at least 30 days post placement. Analysis includes calculation of the unaided soundfield thresholds minus aided soundfield thresholds.
Change in Aided HINT 90 Speech Reception Thresholds (SRTs) When Compared to the Baseline Unaided Condition.
Change in aided HINT 90 speech reception thresholds (SRTs) when compared to the baseline unaided condition. SRTs will be measured using HINT materials with the signal (speech level presented from 0 degrees) adapted relative to the noise (presented from 90 degrees held fixed at 60 dB SPL) to determine the signal-to-noise ratio for reporting the whole sentence correct 50% of the time (Nilsson et al., 1994). An improvement in HINT score is indicated as a negative (-) dB value change. A more negative value indicating an improvement of understanding speech and noise. An improvement of -1dB is equivalent to a 10% improvement in understanding speech and noise and is likely of clinical benefit. HINT 90 will be measured twice and averaged to obtain the per subject HINT SRT. All subject data will be averaged to obtain the means. Analysis includes calculation of the unaided measurements (before device placement) minus the aided measurements.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02042404
Brief Title
The EarLens System Long Term Safety and Efficacy Definitive Multi-Center Study
Official Title
The EarLens System Long Term Safety and Efficacy Definitive Multi-Center Study
Study Type
Interventional
2. Study Status
Record Verification Date
January 2016
Overall Recruitment Status
Completed
Study Start Date
March 2014 (undefined)
Primary Completion Date
January 2015 (Actual)
Study Completion Date
March 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
EarLens Corporation
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The EarLens System is an assistive hearing device that is intended to provide amplification for the treatment of patients with sensorineural hearing impairment. The purpose of this multi-center definitive study is to assess the safety and efficacy of the EarLens System for subjects with bilateral mild to severe sensorineural hearing impairments wearing the fully activated system in their daily lives for a 4 month period of time. This study is designed to support US and International marketing applications to commercialize the EarLens System. The main efficacy hypothesis is that the EarLens System will be shown to improve speech understanding in quiet.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hearing Impairment
Keywords
Hearing impairment, Hearing loss
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
48 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Mild to severe hearing impairment
Arm Type
Experimental
Arm Description
Sound amplification provided via the EarLens System assistive hearing device.
Intervention Type
Device
Intervention Name(s)
Sound amplification provided via EarLens System.
Intervention Description
The EarLens System has two primary components: 1) an external Behind the Ear (BTE) Sound Processing Unit, and 2) a Tympanic Membrane Transducer (TM Transducer). In this system, light is used to wirelessly transmit both signal and power from the BTE Sound Processor to the TM Transducer. The BTE is designed to be able to be removed, reprogrammed, and have the battery recharged as needed, similar to a BTE for an air conduction hearing aid. The removable TM Transducer is customized for each patient, is placed and removed by a physician in an office visit procedure, and is designed to reside in the ear in a safe and stable manner for long periods of time.
Primary Outcome Measure Information:
Title
Change in Mean Aided Word Recognition Scores (WRS) When Compared to the Baseline Unaided Condition.
Description
Change in mean aided Word Recognition Scores (WRS) when compared to the baseline unaided condition. WRS will be measured using 50-word NU-6 (Northwestern University Auditory Test No.6) recorded materials, presented at 45 dB Hearing Level on a per-ear basis with the test ear isolated for measurement and the results, expressed as a percentage of words correct, averaged across the two ears for each subject. All subject data will then be averaged to obtain the means. The baseline unaided measurements will occur prior to device placement, and the aided condition will be measured at least 30 days post device placement.
Time Frame
Baseline and 30 days
Title
Audiometric Safety as Shown by no Hearing Change Pre and Post Treatment
Description
The unaided air conduction hearing thresholds will be measured for each individual ear twice before device placement at Visit #1 and averaged to obtain the baseline unaided air conduction hearing thresholds, and the post wear unaided air conduction hearing thresholds will be measured after device removal at Visit #5. A PTA4 (Pure Tone Average at 4 frequencies; 500, 1000, 2000, and 4000 Hz) will be computed both for baseline unaided hearing pre-placement and unaided hearing post-removal for each ear, then averaged across both ears for each subject . A determination of "No Hearing Change" for the subject population will be made if the calculated Hearing Changes of the subject population are 10 dB or less.
Time Frame
Baseline and 120 days
Secondary Outcome Measure Information:
Title
Functional Gain Over the Frequency Range From 2000 to 10,000 Hz
Description
10 dB (decibel) change in the averaged pure tone thresholds for the subject population over the frequency range from 2000 to 10,000 Hz (2000, 3000, 4000, 6000, 8000, 9000 and 10,000 Hz). Measurement to be used in analysis are the baseline unaided soundfield thresholds measured prior to device placement and the aided soundfield thresholds measured at least 30 days post placement. Analysis includes calculation of the unaided soundfield thresholds minus aided soundfield thresholds.
Time Frame
Baseline and 30 days
Title
Change in Aided HINT 90 Speech Reception Thresholds (SRTs) When Compared to the Baseline Unaided Condition.
Description
Change in aided HINT 90 speech reception thresholds (SRTs) when compared to the baseline unaided condition. SRTs will be measured using HINT materials with the signal (speech level presented from 0 degrees) adapted relative to the noise (presented from 90 degrees held fixed at 60 dB SPL) to determine the signal-to-noise ratio for reporting the whole sentence correct 50% of the time (Nilsson et al., 1994). An improvement in HINT score is indicated as a negative (-) dB value change. A more negative value indicating an improvement of understanding speech and noise. An improvement of -1dB is equivalent to a 10% improvement in understanding speech and noise and is likely of clinical benefit. HINT 90 will be measured twice and averaged to obtain the per subject HINT SRT. All subject data will be averaged to obtain the means. Analysis includes calculation of the unaided measurements (before device placement) minus the aided measurements.
Time Frame
Baseline and 30 days
Other Pre-specified Outcome Measures:
Title
Determine the Incidence of Serious Device- and Procedure-related Adverse Events.
Description
The analysis of the incidence of serious device- and procedure-related adverse events through the study period. All adverse events will be recorded on case report forms and determinations will be made as to the whether the events are related to the investigational device.
Time Frame
120 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age 18 to 85 years
Mild to severe hearing impairment between 125 to 4000 Hz
No significant conductive hearing impairment
Able and willing to commit to travel and time demands of the study
Exclusion Criteria:
Must not have known or active medical issues that would preclude having a device including:
an abnormal tympanic membrane
an abnormal middle ear or history of prior middle ear surgery other than tympanostomy tubes
an ear canal anatomy that prevents physicians from seeing adequate amount of the tympanic membrane
Must not have other known or active medical issues including:
history of chronic and recurrent ear infections in the past 24 mouths
history of dizziness and/or vertigo in the past 24 months
taking medications/treatments with known ototoxic effects
a rapidly progressive or fluctuating hearing impairment
having been diagnosed with having a compromised immune system
Must not fit the definition of a vulnerable subject, as per FDA regulations 21 CFR Parts 50 and 56
Must not have an ear canal anatomy that preclude manufacture of the device as determined by EarLens manufacturing personnel
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bruce Gantz, M.D.
Organizational Affiliation
University of Iowa Dept of Otolaryngology--Head and Neck Surgery University of Iowa Hospitals and Clinics
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Sunil Puria, Ph.D.
Organizational Affiliation
EarLens Corp.
Official's Role
Study Chair
Facility Information:
Facility Name
EarLens Corporation
City
Menlo Park
State/Province
California
ZIP/Postal Code
94025
Country
United States
Facility Name
Camino Ear Nose and Throat Clinic
City
San Jose
State/Province
California
ZIP/Postal Code
95138
Country
United States
Facility Name
University of Iowa Hospitals and Clinics
City
Iowa City
State/Province
Iowa
ZIP/Postal Code
52242
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
23524632
Citation
Fay JP, Perkins R, Levy SC, Nilsson M, Puria S. Preliminary evaluation of a light-based contact hearing device for the hearing impaired. Otol Neurotol. 2013 Jul;34(5):912-21. doi: 10.1097/MAO.0b013e31827de4b1.
Results Reference
background
PubMed Identifier
30300158
Citation
Arbogast TL, Moore BCJ, Puria S, Dundas D, Brimacombe J, Edwards B, Carr Levy S. Achieved Gain and Subjective Outcomes for a Wide-Bandwidth Contact Hearing Aid Fitted Using CAM2. Ear Hear. 2019 May/Jun;40(3):741-756. doi: 10.1097/AUD.0000000000000661.
Results Reference
derived
Links:
URL
http://www.earlenscorp.com
Description
EarLens Corporation website
Learn more about this trial
The EarLens System Long Term Safety and Efficacy Definitive Multi-Center Study
We'll reach out to this number within 24 hrs